comparemela.com


Search jobs
28-Jun-2021
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer's Disease in Greater China
DGAP-News: Vivoryon Therapeutics N.V.
/ Key word(s): Agreement
29.06.2021 / 01:03
The issuer is solely responsible for the content of this announcement.
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer's Disease in Greater China
Halle (Saale)/Munich, Germany and Nanjing, China, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and Simcere Pharmaceutical Group Ltd (HKEX: 2096) (Simcere) today announced that they have entered into a strategic regional licensing partnership to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease (AD) in Greater China.

Related Keywords

China ,Germany ,Nanjing ,Jiangsu ,Ekevin Oliver ,Jason Bao ,Sophia Hergenhan ,Manuela Bader ,Michael Schaeffer ,Simcere Announce Strategic Regional Licensing Partnership To ,Head Of Global Business Development At Simcere ,Simcere Pharmaceutical Group ,Trophic Communications ,Simcere Pharmaceutical Group Ltd ,Distribution Services ,Treat Alzheimer ,Euronext Amsterdam ,Greater China ,Chief Business ,Senior Vice President ,Global Business Development ,Pharmaceutical Group Limited ,Simcere Pharmaceutical Group Limited ,Board Secretary ,Corporate News ,Regulatory Announcements ,சீனா ,ஜெர்மனி ,நான்ஜிங் ,கெவின் ஆலிவர் ,ஜேசன் பாவோ ,மைக்கேல் ஸ்கேஃபர் ,விநியோகம் சேவைகள் ,உபசரிப்பு முதுமறதி ,அதிகமானது சீனா ,தலைமை வணிக ,மூத்தவர் துணை ப்ரெஸிடெஂட் ,உலகளாவிய வணிக வளர்ச்சி ,மருந்து குழு வரையறுக்கப்பட்டவை ,பலகை செயலாளர் ,பெருநிறுவன செய்தி ,ஒழுங்குமுறை அறிவிப்புகள் ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.